Summit Therapeutics (SMMT) Remains an Under-the-Radar DMD Play to Watch - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Summit Therapeutics plc (NASDAQ: SMMT), saying the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
